cagrilintide vs petrelintide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanisms: Amylin receptor · Amylin/calcitonin receptor (dual) · full Obesity pipeline
cagrilintide
Developed by Novo Nordisk
NCT03856047 · Phase 2 · completed
The trial randomized participants to five active doses, a pooled placebo, and an active liraglutide comparator arm, with quadruple-blinding (participant, care provider, investigator, and outcomes assessor all masked) and roughly 100 participants per arm. The primary endpoint, percent change in body weight at 26 weeks, is the regulator-accepted physiological measure for obesity trials, and every cagrilintide dose showed a statistically significant weight-loss advantage over placebo (p-values ranging from 0.0002 to <.0001), so the primary comparison was clearly met in the favorable direction.
Next expected readout: January 2027 · NCT07411560 (registry estimate)
Reported efficacy
Change in Body Weight (%) (From baseline (week 0) to week 26): Change in Body Weight (%) (From baseline (week 0) to week 26): Cagrilintide 0.3 mg -6.1% (Standard Deviation 3.9) | Cagrilintide 0.6 mg -6.9% (Standard Deviation 5.4) | Cagrilintide 1.2 mg -8.5% (Standard Deviation 5.4) | Cagrilintide 2.4 mg -9.5% (Standard Deviation 6.2) | Cagrilintide 4.5 mg -10.8% (Standard Deviation 5.5) vs Liraglutide 3.0 mg -8.5% (Standard Deviation 5.6) | Pooled Placebo -3% (Standard Deviation 5.2) (met)
Result source: NCT03856047
petrelintide
Developed by Zealand Pharma and partners
NCT06662539 · Phase 2 · completed
The study was randomized and double-blind, used matching placebo, and enrolled 493 participants. Its primary clinical endpoint was change in body weight, but the outcome comparison is not yet available because results have not been posted.
Next expected readout: November 2027 · NCT07589686 (registry estimate)
Reported efficacy
Percent change from baseline in body weight to Week 28 (From Baseline (Day 1) to Week 28): Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05). (met)
Result source: NCT06662539
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | cagrilintide | petrelintide |
|---|---|---|
| Body weight, % change | -10.8% vs -3%−7.8 vs placeboNCT038560474 other results
| —Trial running · NCT07843485 |
| Weight loss of 5% or more | 88.7% vs 30.9%+57.8 vs placeboNCT038560474 other results
| —Trial running · NCT07843485 |
| Weight loss of 10% or more | 53.5% vs 10.4%+43.1 vs placeboNCT038560474 other results
| —Trial running · NCT07843485 |
| Waist circumference, change (cm) | -9.5 vs -3.4−6.1 vs placeboNCT038560474 other results
| —Trial running · NCT07843485 |
Body weight, % change
- cagrilintide
- -10.8% vs -3%−7.8 vs placeboNCT03856047
4 other results
- -9.5% vs -3% NCT03856047
- -8.5% vs -3% NCT03856047
- -6.9% vs -3% NCT03856047
- -6.1% vs -3% NCT03856047
- petrelintide
- —Trial running · NCT07843485
Weight loss of 5% or more
- cagrilintide
- 88.7% vs 30.9%+57.8 vs placeboNCT03856047
4 other results
- 74.1% vs 30.9% NCT03856047
- 75.8% vs 30.9% NCT03856047
- 62.0% vs 30.9% NCT03856047
- 57.5% vs 30.9% NCT03856047
- petrelintide
- —Trial running · NCT07843485
Weight loss of 10% or more
- cagrilintide
- 53.5% vs 10.4%+43.1 vs placeboNCT03856047
4 other results
- 44.0% vs 10.4% NCT03856047
- 35.8% vs 10.4% NCT03856047
- 24.1% vs 10.4% NCT03856047
- 15.3% vs 10.4% NCT03856047
- petrelintide
- —Trial running · NCT07843485
Waist circumference, change (cm)
- cagrilintide
- -9.5 vs -3.4−6.1 vs placeboNCT03856047
4 other results
- -8.1 vs -3.4 NCT03856047
- -7.7 vs -3.4 NCT03856047
- -6.2 vs -3.4 NCT03856047
- -6.2 vs -3.4 NCT03856047
- petrelintide
- —Trial running · NCT07843485
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. cagrilintide: 3 of 4 rows · petrelintide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | cagrilintide |
|---|---|
| Dropout rate | 6.9%4.5 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 show 4 more results1%2.4 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 3.9%1.2 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 3%0.6 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 4%0.3 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 |
| Discontinued due to AEs | —4.5 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 show 4 more results—2.4 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 —1.2 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 —0.6 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 —0.3 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 |
| Serious AEs | 4%4.5 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 show 4 more results2.9%2.4 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 6.9%1.2 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 2%0.6 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 5.9%0.3 mg NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 |
| Most frequent reported AEs | 4.5 mg nausea 46.5% (placebo 17.8%) constipation 20.8% (placebo 6.9%) fatigue 19.8% (placebo 3%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 show 4 more results2.4 mg nausea 31.4% (placebo 17.8%) diarrhoea 17.6% (placebo 8.9%) constipation 16.7% (placebo 6.9%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 1.2 mg nausea 36.3% (placebo 17.8%) nasopharyngitis 12.7% (placebo 9.9%) headache 10.8% (placebo 11.9%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 0.6 mg nausea 27% (placebo 17.8%) diarrhoea 10% (placebo 8.9%) constipation 9% (placebo 6.9%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 0.3 mg nausea 19.8% (placebo 17.8%) diarrhoea 14.9% (placebo 8.9%) constipation 10.9% (placebo 6.9%) NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
cagrilintide
show 4 more results
show 4 more results
show 4 more results
show 4 more results
show 4 more results
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cagrilintide's landscape · petrelintide's landscape